Developer docs
API playgroundTry for free, no card

Search company profiles

EuroAPI

Full company profile

uuid0000gbx

Namestring
EuroAPI
Legal namestring
EUROAPI
Websiteurl
euroapi.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

EuroAPI, headquartered in Paris and listed on Euronext Paris (ticker EAPI) since May 2022 following its spin-off from Sanofi, is a leading developer, manufacturer, and supplier of Active Pharmaceutical Ingredients (APIs) with approximately 200 products in its portfolio covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small and complex molecules. The company operates six cGMP-compliant manufacturing sites across Europe (France, Germany, Hungary, Italy, with a UK site divested in June 2025) and serves customers in more than 80 countries through a direct enterprise sales model targeting pharmaceutical companies, biotech firms, and innovative drug developers. Its core technology spans API manufacturing and Contract Development and Manufacturing Organization (CDMO) services across small molecules, complex molecules, oligonucleotides, lipid nanoparticles (including cationic lipids for mRNA delivery), and microbial fermentation, supported by approximately 330 scientists and state-of-the-art large-scale chromatography purification equipment.

EuroAPI generates revenue through two streams: API Solutions (commercial sale of ~200 catalog APIs) and CDMO Services (custom development and GMP manufacturing for oligonucleotides, lipids, small molecules, microbial fermentation, and particle engineering). The CDMO segment is a strategic priority and is targeted to reach approximately 35% of total net sales by end of 2025. The company maintains a deeply entrenched relationship with Sanofi — its former parent — through a Master Agreement for Development and GMP Manufacturing Services covering ten projects in Sanofi's R&D portfolio and mRNA vaccine platform support. Sanofi remains a major shareholder with approximately 30% ownership and subscribed to a €200M hybrid bond in October 2024 alongside EPIC Bpifrance (12%).

The business is currently executing a portfolio transformation under its FOCUS-27 strategic plan, including €451M revolving credit facility refinancing, divestiture of the Haverhill site to Particle Dynamics in June 2025, and ongoing strategic review of the Brindisi site with a 2027 conclusion target. 2025 net sales consensus stands at €850.6M from five contributing analysts, with management reaffirming a 7-9% EBITDA margin target while guiding to a mid-single-digit revenue decline for 2025.

Short descriptiontext

EuroAPI is a Paris-listed manufacturer of approximately 200 Active Pharmaceutical Ingredients and CDMO services spanning oligonucleotides, lipid nanoparticles, small molecules, and microbial fermentation, serving pharmaceutical and biotech companies across 80+ countries from six European manufacturing sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, contract development manufacturing, oligonucleotide CDMO services, lipid nanoparticle manufacturing, small molecule synthesis
Industry5 codes
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAC
High-Potency API (HPAPI) Development & Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Active Pharmaceutical Ingredients (API) Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1API Solutions
TypeOne Time License
Description

Sale of Active Pharmaceutical Ingredients including approximately 200 products covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small/complex molecules to pharmaceutical companies globally.

euroapi.com
2CDMO Services
TypeSubscription Recurring
Description

Contract Development and Manufacturing Organization services offering custom development and GMP manufacturing for oligonucleotides, lipids, small molecules, microbial fermentation, and particle engineering. Strategic priority expected to reach ~35% of total net sales by end of 2025.

euroapi.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EuroAPI develops, manufactures, and supplies one of the world's largest portfolios of Active Pharmaceutical Ingredients (APIs), with approximately 200 products covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small and complex molecules, distributed to pharmaceutical companies in 80+ countries. In parallel, the company operates a CDMO (Contract Development and Manufacturing Organization) business offering custom development and GMP manufacturing for oligonucleotides, small molecules, lipid nanoparticles (LNPs) for mRNA delivery, particle engineering/micronization, microbial fermentation (enzymes), prostaglandins, and steroids and hormones. The combined offering serves both catalog API supply and tailored contract manufacturing from preclinical to commercial scale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CDMO activity expected to reach ~35% of total net sales by end of 2025
+2 more records
Product overview1 text field

EuroAPI operates as both an API manufacturer and CDMO (Contract Development and Manufacturing Organization). The API Solutions segment offers approximately 200 active pharmaceutical ingredients across categories including Vitamin B12, Prostaglandins, Corticoids & Hormones, Anti Infectives, Opiates & Controlled Substances, Small and Complex Molecules, Intermediates and Reagents. The CDMO Services segment provides specialized contract manufacturing across multiple technology platforms: Tides (Oligonucleotides), Small Molecules Synthesis, Lipids, Particle Engineering (Micronization), Microbial Fermentation (Enzymes), Prostaglandins, and Steroids and Hormones. These two segments serve distinct customer needs—the API Solutions for standard pharmaceutical ingredient supply and the CDMO for innovative, complex molecule development and manufacturing.

Product and service8 records
1API Solutions
CategoryActive Pharmaceutical Ingredients
Description

EuroAPI's catalog offering of approximately 200 Active Pharmaceutical Ingredients spanning Vitamin B12, Prostaglandins, Corticoids & Hormones, Anti-Infectives, Opiates & Controlled Substances, Small and Complex Molecules, Intermediates and Reagents, addressing both human and animal health, supplied to pharmaceutical companies in 80+ countries.

2Tides / Oligonucleotide CDMO
CategoryCDMO Services
Description

Contract Development and Manufacturing Organization services for oligonucleotides (Tides), from preclinical through commercial production, including analytical services and GMP manufacturing, leveraging capabilities acquired from BianoGMP.

3Small Molecules Synthesis CDMO
CategoryCDMO Services
Description

Contract development and manufacturing services for small molecule synthesis, leveraging EuroAPI's expertise in complex chemistry and 330 scientists across analytics and regulatory.

4Lipids CDMO
CategoryCDMO Services
Description

Contract development and GMP manufacturing services for lipid nanoparticles (LNPs) and cationic lipids used in mRNA vaccine delivery and therapeutic nucleic acid delivery, with state-of-the-art large-scale chromatography purification equipment at Budapest and Frankfurt sites.

5Particle Engineering CDMO (Micronization)
CategoryCDMO Services
Description

Particle engineering CDMO services including micronization for optimizing Active Pharmaceutical Ingredient physical properties, leveraging specialized equipment at EuroAPI's manufacturing sites.

6Microbial Fermentation CDMO (Enzymes)
CategoryCDMO Services
Description

Contract development and manufacturing services leveraging microbial fermentation technology for enzyme and biologics production.

7Prostaglandins CDMO
CategoryCDMO Services
Description

Contract development and manufacturing services for prostaglandin synthesis and manufacturing, addressing specialized therapeutic applications.

8Steroids and Hormones CDMO
CategoryCDMO Services
Description

Contract development and manufacturing services for steroid and hormone Active Pharmaceutical Ingredients, supporting both human and animal health applications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Strategic partnership to develop microbial strains for corticosteroid production as part of European IPCEI initiative to enhance pharmaceutical sovereignty. Project supported by up to €140 million from France 2030 via Bpifrance, aiming to reduce Europe's reliance on Asian manufacturers.

2Med4Cure Program Partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Med4Cure innovation programs launched at Vertolaye site involving multiple startups, academic institutions, and industry partners to develop advanced manufacturing processes for APIs. Supported by European Commission's Health IPCEI initiative and France 2030 to secure supply chains and bolster drug production in Europe.

globenewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-30
Description

Expanded collaboration under Master Agreement for Development and GMP Manufacturing Services (DSA) to support Sanofi's mRNA vaccine platform with lipid nanoparticle development. EUROAPI develops and manufactures GMP batches for cationic lipids for Phase I/II clinical trials targeting indications including Flu. Sanofi is also a major shareholder with 30% stake and has provided €200 million hybrid bond financing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Master Agreement for Development and GMP Manufacturing Services (DSA) signed October 2021. Engaged in ten projects to develop and/or manufacture new molecular entities in Sanofi's R&D portfolio. Sanofi also subscribed to €200 million hybrid bond and reserved €54 million capacity for five products.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss-listed API manufacturer with comparable small-molecule and complex API portfolio across steroids, controlled substances, and custom manufacturing for pharma customers. Operates similar European manufacturing footprint with overlapping therapeutic categories to EuroAPI.

TypeBroad incumbent
Description

Global CDMO leader offering contract development and manufacturing across small molecules, biologics, and cell & gene therapies. Competes with EuroAPI's CDMO services, particularly in mammalian/cell culture and complex APIs, though significantly larger and more diversified.

TypeDirect peer
Description

Portuguese-headquartered CDMO specializing in complex small molecules, particle engineering, and GMP manufacturing — directly overlapping with EuroAPI's Particle Engineering, Small Molecules Synthesis, and complex chemistry CDMO offerings.

TypeDirect peer
Description

US/EU-based contract API manufacturer with comparable small-molecule and controlled-substance capabilities. Recently private-equity owned and competing for similar CDMO projects in pre-clinical through commercial stages as EuroAPI.

5Recipharm
TypeDirect peer
Description

Swedish CDMO offering contract development and manufacturing for small-molecule APIs across multiple European sites. Comparable customer base of generic and innovative pharma customers and similar scale of CDMO services to EuroAPI.

TypeBroad incumbent
Description

Chinese-based global CDMO providing small-molecule API and oligonucleotide development/manufacturing at scale. Direct competitor for oligonucleotide CDMO projects and a key Asian low-cost alternative to EuroAPI's CDMO services.

TypeBroad incumbent
Description

Major US/global CDMO recently taken private by Novo Holdings, providing API development, particle engineering, and complex formulation services that overlap with EuroAPI's CDMO portfolio at larger scale and broader scope.

TypeBroad incumbent
Description

Part of Thermo Fisher's pharma services division, offering API manufacturing and integrated CDMO services. Competes with EuroAPI for complex API contracts and is substantially larger with broader capabilities.

TypeRegional player
Description

Indian API manufacturer and CDMO with strong position in corticosteroids, peptides, and generic APIs — directly competing with EuroAPI in corticoids and complex generics from a low-cost Asian manufacturing base.

TypeRegional player
Description

Large Indian generic pharmaceutical and API manufacturer with significant presence in anti-infectives, hormones, and small-molecule APIs. Competes with EuroAPI's API Solutions business from a lower-cost manufacturing base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EuroAPI

Active Pharmaceutical Ingredients (API) Manufacturingeuroapi.com

EuroAPI is a Paris-listed manufacturer of approximately 200 Active Pharmaceutical Ingredients and CDMO services spanning oligonucleotides, lipid nanoparticles, small molecules, and microbial fermentation, serving pharmaceutical and biotech companies across 80+ countries from six European manufacturing sites.

What EuroAPI does

EuroAPI, headquartered in Paris and listed on Euronext Paris (ticker EAPI) since May 2022 following its spin-off from Sanofi, is a leading developer, manufacturer, and supplier of Active Pharmaceutical Ingredients (APIs) with approximately 200 products in its portfolio covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small and complex molecules. The company operates six cGMP-compliant manufacturing sites across Europe (France, Germany, Hungary, Italy, with a UK site divested in June 2025) and serves customers in more than 80 countries through a direct enterprise sales model targeting pharmaceutical companies, biotech firms, and innovative drug developers. Its core technology spans API manufacturing and Contract Development and Manufacturing Organization (CDMO) services across small molecules, complex molecules, oligonucleotides, lipid nanoparticles (including cationic lipids for mRNA delivery), and microbial fermentation, supported by approximately 330 scientists and state-of-the-art large-scale chromatography purification equipment.

EuroAPI generates revenue through two streams: API Solutions (commercial sale of ~200 catalog APIs) and CDMO Services (custom development and GMP manufacturing for oligonucleotides, lipids, small molecules, microbial fermentation, and particle engineering). The CDMO segment is a strategic priority and is targeted to reach approximately 35% of total net sales by end of 2025. The company maintains a deeply entrenched relationship with Sanofi — its former parent — through a Master Agreement for Development and GMP Manufacturing Services covering ten projects in Sanofi's R&D portfolio and mRNA vaccine platform support. Sanofi remains a major shareholder with approximately 30% ownership and subscribed to a €200M hybrid bond in October 2024 alongside EPIC Bpifrance (12%).

The business is currently executing a portfolio transformation under its FOCUS-27 strategic plan, including €451M revolving credit facility refinancing, divestiture of the Haverhill site to Particle Dynamics in June 2025, and ongoing strategic review of the Brindisi site with a 2027 conclusion target. 2025 net sales consensus stands at €850.6M from five contributing analysts, with management reaffirming a 7-9% EBITDA margin target while guiding to a mid-single-digit revenue decline for 2025.

EuroAPI firmographics

Firmographics
Name
EuroAPI
Legal name
EUROAPI
Website
https://euroapi.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
EuroAPI is a Paris-listed manufacturer of approximately 200 Active Pharmaceutical Ingredients and CDMO services spanning oligonucleotides, lipid nanoparticles, small molecules, and microbial fermentation, serving pharmaceutical and biotech companies across 80+ countries from six European manufacturing sites.
Ownership category
akta.pro rank

EuroAPI industry classification

Industry
Product category
Active Pharmaceutical Ingredients (API) Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAC
High-Potency API (HPAPI) Development & Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Active pharmaceutical ingredients
  • Contract development manufacturing
  • Oligonucleotide CDMO services
  • Lipid nanoparticle manufacturing
  • Small molecule synthesis

Where EuroAPI is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices6 records

Markets served

EuroAPI business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. API Solutions: Sale of Active Pharmaceutical Ingredients including approximately 200 products covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small/complex molecules to pharmaceutical companies globally.
  2. CDMO Services: Contract Development and Manufacturing Organization services offering custom development and GMP manufacturing for oligonucleotides, lipids, small molecules, microbial fermentation, and particle engineering. Strategic priority expected to reach ~35% of total net sales by end of 2025.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

EuroAPI product offering

Product offering

Core offering

EuroAPI develops, manufactures, and supplies one of the world's largest portfolios of Active Pharmaceutical Ingredients (APIs), with approximately 200 products covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small and complex molecules, distributed to pharmaceutical companies in 80+ countries. In parallel, the company operates a CDMO (Contract Development and Manufacturing Organization) business offering custom development and GMP manufacturing for oligonucleotides, small molecules, lipid nanoparticles (LNPs) for mRNA delivery, particle engineering/micronization, microbial fermentation (enzymes), prostaglandins, and steroids and hormones. The combined offering serves both catalog API supply and tailored contract manufacturing from preclinical to commercial scale.

Product overview

EuroAPI operates as both an API manufacturer and CDMO (Contract Development and Manufacturing Organization). The API Solutions segment offers approximately 200 active pharmaceutical ingredients across categories including Vitamin B12, Prostaglandins, Corticoids & Hormones, Anti Infectives, Opiates & Controlled Substances, Small and Complex Molecules, Intermediates and Reagents. The CDMO Services segment provides specialized contract manufacturing across multiple technology platforms: Tides (Oligonucleotides), Small Molecules Synthesis, Lipids, Particle Engineering (Micronization), Microbial Fermentation (Enzymes), Prostaglandins, and Steroids and Hormones. These two segments serve distinct customer needs—the API Solutions for standard pharmaceutical ingredient supply and the CDMO for innovative, complex molecule development and manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • API Solutions EuroAPI's catalog offering of approximately 200 Active Pharmaceutical Ingredients spanning Vitamin B12, Prostaglandins, Corticoids & Hormones, Anti-Infectives, Opiates & Controlled Substances, Small and Complex Molecules, Intermediates and Reagents, addressing both human and animal health, supplied to pharmaceutical companies in 80+ countries.
  • Tides / Oligonucleotide CDMO Contract Development and Manufacturing Organization services for oligonucleotides (Tides), from preclinical through commercial production, including analytical services and GMP manufacturing, leveraging capabilities acquired from BianoGMP.
  • Small Molecules Synthesis CDMO Contract development and manufacturing services for small molecule synthesis, leveraging EuroAPI's expertise in complex chemistry and 330 scientists across analytics and regulatory.
  • Lipids CDMO Contract development and GMP manufacturing services for lipid nanoparticles (LNPs) and cationic lipids used in mRNA vaccine delivery and therapeutic nucleic acid delivery, with state-of-the-art large-scale chromatography purification equipment at Budapest and Frankfurt sites.
  • Particle Engineering CDMO (Micronization) Particle engineering CDMO services including micronization for optimizing Active Pharmaceutical Ingredient physical properties, leveraging specialized equipment at EuroAPI's manufacturing sites.
  • Microbial Fermentation CDMO (Enzymes) Contract development and manufacturing services leveraging microbial fermentation technology for enzyme and biologics production.
  • Prostaglandins CDMO Contract development and manufacturing services for prostaglandin synthesis and manufacturing, addressing specialized therapeutic applications.
  • Steroids and Hormones CDMO Contract development and manufacturing services for steroid and hormone Active Pharmaceutical Ingredients, supporting both human and animal health applications.

Quantifiable outcome

  • CDMO activity expected to reach ~35% of total net sales by end of 2025
  • +2 more outcomes

Companies that use EuroAPI

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

EuroAPI technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EuroAPI partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic and core.

  • Abolis BiotechnologiesstrategicStrategic or Co-development Partner · 24 October 2025Strategic partnership to develop microbial strains for corticosteroid production as part of European IPCEI initiative to enhance pharmaceutical sovereignty. Project supported by up to €140 million from France 2030 via Bpifrance, aiming to reduce Europe's reliance on Asian manufacturers.
  • Med4Cure Program PartnersstrategicStrategic or Co-development Partner · 23 October 2025Med4Cure innovation programs launched at Vertolaye site involving multiple startups, academic institutions, and industry partners to develop advanced manufacturing processes for APIs. Supported by European Commission's Health IPCEI initiative and France 2030 to secure supply chains and bolster drug production in Europe.
  • SanoficoreStrategic or Co-development Partner · 30 May 2022Expanded collaboration under Master Agreement for Development and GMP Manufacturing Services (DSA) to support Sanofi's mRNA vaccine platform with lipid nanoparticle development. EUROAPI develops and manufactures GMP batches for cationic lipids for Phase I/II clinical trials targeting indications including Flu. Sanofi is also a major shareholder with 30% stake and has provided €200 million hybrid bond financing.
  • Sanofi (DSA Agreement)coreStrategic or Co-development Partner · 1 October 2021Master Agreement for Development and GMP Manufacturing Services (DSA) signed October 2021. Engaged in ten projects to develop and/or manufacture new molecular entities in Sanofi's R&D portfolio. Sanofi also subscribed to €200 million hybrid bond and reserved €54 million capacity for five products.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

EuroAPI competitors and assessment

Company assessment

Direct peers

  • Siegfried Holding: Swiss-listed API manufacturer with comparable small-molecule and complex API portfolio across steroids, controlled substances, and custom manufacturing for pharma customers. Operates similar European manufacturing footprint with overlapping therapeutic categories to EuroAPI.
  • Hovione: Portuguese-headquartered CDMO specializing in complex small molecules, particle engineering, and GMP manufacturing — directly overlapping with EuroAPI's Particle Engineering, Small Molecules Synthesis, and complex chemistry CDMO offerings.
  • Cambrex (Permira-owned): US/EU-based contract API manufacturer with comparable small-molecule and controlled-substance capabilities. Recently private-equity owned and competing for similar CDMO projects in pre-clinical through commercial stages as EuroAPI.
  • Recipharm: Swedish CDMO offering contract development and manufacturing for small-molecule APIs across multiple European sites. Comparable customer base of generic and innovative pharma customers and similar scale of CDMO services to EuroAPI.

Broad incumbents

  • Lonza Group: Global CDMO leader offering contract development and manufacturing across small molecules, biologics, and cell & gene therapies. Competes with EuroAPI's CDMO services, particularly in mammalian/cell culture and complex APIs, though significantly larger and more diversified.
  • WuXi STA (WuXi AppTec): Chinese-based global CDMO providing small-molecule API and oligonucleotide development/manufacturing at scale. Direct competitor for oligonucleotide CDMO projects and a key Asian low-cost alternative to EuroAPI's CDMO services.
  • Catalent (Novo Holdings): Major US/global CDMO recently taken private by Novo Holdings, providing API development, particle engineering, and complex formulation services that overlap with EuroAPI's CDMO portfolio at larger scale and broader scope.
  • Patheon (Thermo Fisher Scientific): Part of Thermo Fisher's pharma services division, offering API manufacturing and integrated CDMO services. Competes with EuroAPI for complex API contracts and is substantially larger with broader capabilities.

Regional players

  • Divi's Laboratories: Indian API manufacturer and CDMO with strong position in corticosteroids, peptides, and generic APIs — directly competing with EuroAPI in corticoids and complex generics from a low-cost Asian manufacturing base.
  • Aurobindo Pharma: Large Indian generic pharmaceutical and API manufacturer with significant presence in anti-infectives, hormones, and small-molecule APIs. Competes with EuroAPI's API Solutions business from a lower-cost manufacturing base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

EuroAPI social profiles

Digital presence

EuroAPI compliance and trust

Trust signal

Compliance1 record

EuroAPI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EuroAPI leadership team

Management profile

Number of profiles

Profiles20 records

EuroAPI subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

EuroAPI funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EuroAPI M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EuroAPI

What does EuroAPI do?

EuroAPI develops, manufactures, and supplies one of the world's largest portfolios of Active Pharmaceutical Ingredients (APIs), with approximately 200 products covering anti-infectives, vitamins, prostaglandins, corticoids, hormones, opiates, and small and complex molecules, distributed to pharmaceutical companies in 80+ countries. In parallel, the company operates a CDMO (Contract Development and Manufacturing Organization) business offering custom development and GMP manufacturing for oligonucleotides, small molecules, lipid nanoparticles (LNPs) for mRNA delivery, particle engineering/micronization, microbial fermentation (enzymes), prostaglandins, and steroids and hormones. The combined offering serves both catalog API supply and tailored contract manufacturing from preclinical to commercial scale.

Is EuroAPI a public or private company?

EuroAPI is a public company. It is classified as public and is currently operating.

When was EuroAPI founded?

EuroAPI was founded in 2020. It employs 1,001 to 5,000 people.

Where is EuroAPI based?

EuroAPI is headquartered in Paris, France, in the Europe region.

How does EuroAPI make money?

Two revenue lines are on record. API Solutions are the primary driver. The others are CDMO Services.

Who are EuroAPI's main competitors?

Direct peers on record are Siegfried Holding, Hovione, Cambrex (Permira-owned) and Recipharm. Broad incumbents are Lonza Group, WuXi STA (WuXi AppTec), Catalent (Novo Holdings) and Patheon (Thermo Fisher Scientific). Regional players are Divi's Laboratories and Aurobindo Pharma.

Does EuroAPI have an API?

No public API is recorded for EuroAPI.

What industry is EuroAPI in?

EuroAPI's product category is Active Pharmaceutical Ingredients (API) Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAC, High-Potency API (HPAPI) Development & Manufacturing. Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ANTARA NewsMedisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical CompoundingMedisca and EUROAPI formed a strategic partnership to expand access to European-manufactured APIs for pharmaceutical compounding, with Medisca as EUROAPI's first strategic distribution partner in North America. The collaboration includes exclusive supply arrangements and plans to add new APIs and explore peptide collaboration.Financial PostMedisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical CompoundingMedisca and EUROAPI formed a strategic partnership to expand API access for pharmaceutical compounding in North America. Medisca becomes EUROAPI's first strategic distribution partner, with exclusive supply arrangements and plans to add APIs and explore peptide collaboration.FinancialContent Business PageMedisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical CompoundingMedisca and EUROAPI formed a strategic partnership to expand access to European-manufactured APIs for pharmaceutical compounding, with Medisca as EUROAPI's first strategic distribution partner in North America. The collaboration includes exclusive supply arrangements and plans to add new APIs and explore peptide collaboration.Business Wire BlogMedisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical CompoundingMedisca and EUROAPI formed a strategic partnership to expand API access for pharmaceutical compounding, with Medisca becoming EUROAPI's first strategic distribution partner for North America. The collaboration includes exclusive supply arrangements and plans to add new APIs and explore peptide collaboration.AETOSWireMedisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical CompoundingMedisca and EUROAPI formed a strategic partnership to expand API access for pharmaceutical compounding, with Medisca becoming EUROAPI's first strategic distribution partner for North America. The collaboration includes exclusive supply arrangements and plans to add new APIs and explore peptide collaboration.SeeNewsBulgaria's Huvepharma to buy Euroapi Italian unitBulgarian health and nutraceuticals company Huvepharma has entered into an agreement to purchase the entire share capital of Euroapi's Italian unit for an enterprise value of 5 million euro. As part of the deal, Euroapi will contribute 60 million euro over a two-year period to finance operating expenses, capital expenditure, and restructuring at its Brindisi production site, which will boost Huvepharma's fermentation capacity by 25% to over 12,000 cubic metres.YahooEUROAPI_Availability of 2026 Half-year results financial reportEUROAPI announced on July 31, 2026, the availability of its 2026 condensed Half Year Consolidated Financial Statements for the six-month period ended June 30, 2026. The report, which includes the half-year management report, consolidated financial statements, and statutory auditors' review, is available on the company's website. This is a routine corporate disclosure announcing the publication of financial documents rather than reporting actual financial results.Seeking AlphaEuroapi S.A. (EAPIF) Q2 2026 Earnings Call TranscriptEuroapi S.A. held its 2026 Half Year Results Presentation featuring CEO David Seignolle and CFO Olivier Falut. The event included a management presentation followed by a Q&A session.Investing.comeuroAPI H1 2026 slides: EBITDA margin falls to 5.8% amid restructuring By Investing.comFrench active pharmaceutical ingredient manufacturer euroAPI reported first-half 2026 results on July 30 revealing deepening losses, with net sales declining 13.5% year-over-year to €356.5 million and net loss widening to €141.5 million from €28.5 million. The company's core EBITDA margin collapsed to 5.8% from 9.6% in the prior-year period, driven by €63.8 million in non-recurring restructuring charges and industrial inefficiencies, while shares fell 26.39% following the announcement. EuroAPI maintained its full-year sales guidance of approximately 10% decline but revised its profitability outlook downward due to Hungarian forint appreciation expected to increase costs by €9 million, alongside progress on the FOCUS-27 transformation including a Brindisi site sale to Huvepharma.BioSpaceFirst-Half 2026 results confirm commercial and operational resilience in a challenging market environment - Transformation progressing as planned, including the divestment of the Brindisi siteEUROAPI reported H1 2026 net sales of €356.5 million, down 13.5% year-on-year, with core EBITDA at €20.7 million. The company signed an agreement to sell its Brindisi site to Huvepharma for €5 million, with a two-year transition. FY 2026 net sales are expected in line with the initial outlook.